Adaptimmune Therapeutics
ADAP
$1.64
Share price
-1.80%
Change (1 day)
-67.78%
Change (1 year)
Categories
Market capitalization of Adaptimmune Therapeutics (ADAP)
Market cap: $0.26 Billion
As of May 2022 Adaptimmune Therapeutics has a market cap of $0.26 Billion. This makes Adaptimmune Therapeutics the world's 5404th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to mesure how much a company is worth.
Market cap history of Adaptimmune Therapeutics from 2015 to 2022
| Year | Market cap | Change |
|---|---|---|
| 2022 | $0.26 B | -54.68% |
| 2021 | $0.58 B | -29.79% |
| 2020 | $0.83 B | 561.11% |
| 2019 | $0.12 B | -79.01% |
| 2018 | $0.60 B | -3.92% |
| 2017 | $0.62 B | 118.3% |
| 2016 | $0.28 B | -66.42% |
| 2015 | $0.85 B |
End of Day market cap according to different sources
On May 21st, 2022 the market cap of Adaptimmune Therapeutics was reported to be:
$0.26 Billion
$0.26 Billion
$0.26 Billion
$0.25 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 uniQure QURE | $0.64 B | 141.09% | 🇳🇱 Netherlands |
 Novavax NVAX | $4.17 B | 1,472.35% | 🇺🇸 USA |
 Exelixis EXEL | $5.69 B | 2,045.86% | 🇺🇸 USA |
 Enzo Biochem ENZ | $0.11 B | -56.33% | 🇺🇸 USA |